CMPX COMPASS THERAPEUTICS INC

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel 2023 Virtual Targeted Oncology Days, which is taking place on April 25 – 26, 2023.

Fireside Chat details:

Date: Wednesday, April 26

Time: 11 AM ET

Webcast:

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ page.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass’s pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. Compass was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics, Inc. website at .

Investor Contact

Media Contact

Anna Gifford, Communications Manager



617-500-8099



EN
19/04/2023

Underlying

CMPXCOMPASS THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on COMPASS THERAPEUTICS INC

 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Announces Proposed Public Offering

Compass Therapeutics Announces Proposed Public Offering BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the launch of an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Compas...

1h / 24m 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Reports 2025 Second Quarter Financial Results and...

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be affecting overall survival in the patient population. As a result, the analysis of the secondary endpoints, including overall survival, is now expected in Q1 2026.In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) in pat...

August 11, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics to Present Second Quarter Financial Results and P...

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025 BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on Monday, August 11, 2025, at 8:00 a.m. ET. Cal...

August 8, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics to Participate in the Jefferies Global Healthcare...

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 3-5, 2025. Fireside Chat DetailsDate: Thursday, June 5, 2025Time: 11:05 – 11:35 AM ETWebcast Link:  Virtual/Replay availability: The fireside chat will be archived for 90 days on Co...

May 28, 2025 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Reports 2025 First Quarter Financial Results and ...

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% ORR for paclitaxel alone, in patients with BTC treated in the second-line setting. First patient dosed and actively enrolling patients in an Investigator Sponsored Trial (IST) evaluating tovecimig in patients with BTC in the first...

May 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch